MF
AEON icon

Magnetar Financial’s AEON Biopharma AEON Stock Holding History

Magnetar Financial’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,613
Closed -$4.06M – 598
2022
Q4 		$4.06M Hold
5,613
– – 0.07% 280
2022
Q3 		$3.98M Buy
5,613
+2,549
+83% +$1.81M 0.06% 394
2022
Q2 		$2.16K Buy
+3,064
New +$2.16M 0.02% 657

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Magnetar Financial's AEON Position: Q1 2023 in Review

Magnetar Financial sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 5,613 shares — an estimated $4.06M sold.

Magnetar Financial first reported a position in AEON in Q2 2022 and held it in 3 quarters. The position peaked at $4.06M in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • Magnetar Financial reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • Magnetar Financial sold 5,613 AEON Biopharma shares in Q1 2023, an estimated $4.06M.
  • Magnetar Financial first reported a position in AEON Biopharma in Q2 2022 and held it in 3 quarters.
  • Magnetar Financial's AEON Biopharma position peaked at $4.06M in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Magnetar Financial's 13F filing for Q1 2023, filed 15 May 2023.